Search Results - "Surinach, A" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Miniaturized head-mounted microscope for whole-cortex mesoscale imaging in freely behaving mice

Miniaturized head-mounted microscope for whole-cortex mesoscale imaging in freely behaving mice

by Rynes, Mathew L, Surinach, Daniel A, Linn, Samantha, Laroque, Michael, Rajendran, Vijay, Dominguez, Judith, Hadjistamoulou, Orestes, Navabi, Zahra S, Ghanbari, Leila, Johnson, Gregory W, Nazari, Mojtaba, Mohajerani, Majid H, Kodandaramaiah, Suhasa B
Published in Nature methods (01.04.2021)

Get full text

Journal Article

Passive water ascent in a tall, scalable synthetic tree

Passive water ascent in a tall, scalable synthetic tree

by Shi, Weiwei, Dalrymple, Richard M, McKenny, Collin J, Morrow, David S, Rashed, Ziad T, Surinach, Daniel A, Boreyko, Jonathan B
Published in Scientific reports (14.01.2020)

Get full text

Journal Article

Self-Stabilizing Transpiration in Synthetic Leaves

Self-Stabilizing Transpiration in Synthetic Leaves

by Shi, Weiwei, Vieitez, Joshua R, Berrier, Austin S, Roseveare, Matthew W, Surinach, Daniel A, Srijanto, Bernadeta R, Collier, C. Patrick, Boreyko, Jonathan B
Published in ACS applied materials & interfaces (10.04.2019)

Get full text

Journal Article

Author Correction: Passive water ascent in a tall, scalable synthetic tree

Author Correction: Passive water ascent in a tall, scalable synthetic tree

by Shi, Weiwei, Dalrymple, Richard M, McKenny, Collin J, Morrow, David S, Rashed, Ziad T, Surinach, Daniel A, Boreyko, Jonathan B
Published in Scientific reports (26.01.2021)

Get full text

Journal Article

Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel

Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel

by Surinach, A, Phung, T, Abdul-Rahim, O, Khushman, M
Published in Current oncology (Toronto) (01.04.2020)

Get full text

Journal Article

Real-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics

Real-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics

by Ahn, D., Barzi, A., Miksad, R.A., Surinach, A., Corvino, F.A., Valderrama, A., Mamlouk, K., Pulgar, S., Bekaii-Saab, T.
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

Methodology Using Pharmacy And Medical Claims Data To Evaluate Real-World Outcomes And Costs Of Ivf Treatment In The Us

Methodology Using Pharmacy And Medical Claims Data To Evaluate Real-World Outcomes And Costs Of Ivf Treatment In The Us

by Corvino, F.A, Surinach, A, Locklear, J.C, Howe, A.M, Hayward, B, Mahony, M.C
Published in Value in health (01.05.2015)

Get full text

Journal Article

Lenalidomide Dose Modifications and Associated Patient Outcomes in Newly Diagnosed Multiple Myeloma (NDMM)

Lenalidomide Dose Modifications and Associated Patient Outcomes in Newly Diagnosed Multiple Myeloma (NDMM)

by Usmani, S, Binder, G, Hu, X.H, Nagarwala, Y, Corvino, F.A, Surinach, A, Lee, J, Hussein, M, Arikian, S.R
Published in Clinical lymphoma, myeloma and leukemia (01.09.2015)

Get full text

Journal Article

Patterns of Growth Factor Costs in Multiple Myeloma Patients Treated With Lenalidomide or Bortezomib

Patterns of Growth Factor Costs in Multiple Myeloma Patients Treated With Lenalidomide or Bortezomib

by Arikian, S.R, Nyandege, A, Binder, G, Hu, X.H, Nagarwala, Y, Hussein, M, Lee, J, Corvino, F.A, Surinach, A, Usmani, S.Z
Published in Clinical lymphoma, myeloma and leukemia (01.09.2015)

Get full text

Journal Article

RWD4 A Real-World Data Landscape Review of the 2023 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference

RWD4 A Real-World Data Landscape Review of the 2023 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference

by Surinach, A, Vijapur, S, Thiel, E
Published in Value in health (01.06.2024)

Get full text

Journal Article

EP14.05-019 Contemporary Real-World Adverse Events Associated with Small Cell Lung Cancer Diagnosed in a U.S. Population from 2013-2021

EP14.05-019 Contemporary Real-World Adverse Events Associated with Small Cell Lung Cancer Diagnosed in a U.S. Population from 2013-2021

by Ramirez, R.A., Surinach, A., Cockrum, P.
Published in Journal of thoracic oncology (01.09.2022)

Get full text

Journal Article

192P Treatment patterns and outcomes of metastatic breast cancer (mBC) patients with HER2 IHC2+/ISH- status in the US

192P Treatment patterns and outcomes of metastatic breast cancer (mBC) patients with HER2 IHC2+/ISH- status in the US

by Macewan, J., Scherrer, E., Surinach, A., Wang, Z.
Published in Annals of oncology (01.05.2022)

Get full text

Journal Article

1513P Real-world treatment discontinuation patterns among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States

1513P Real-world treatment discontinuation patterns among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States

by Kim, G., Surinach, A., Wang, S., Lamarre, N., Cockrum, P.
Published in Annals of oncology (01.09.2021)

Get full text

Journal Article

1480P Real-world progression outcomes among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States

1480P Real-world progression outcomes among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States

by Kim, G., Cockrum, P., Surinach, A., Wang, S., Lamarre, N.
Published in Annals of oncology (01.09.2021)

Get full text

Journal Article

CO37 Real-World 30-Day Readmission Patterns Among Commercially Insured Patients with Metastatic Pancreatic Ductal Adenocarcinoma (MPDAC)

CO37 Real-World 30-Day Readmission Patterns Among Commercially Insured Patients with Metastatic Pancreatic Ductal Adenocarcinoma (MPDAC)

by Kim, GP, Surinach, A, Cockrum, P
Published in Value in health (01.07.2022)

Get full text

Journal Article

CO119 Real-World "Chair-Time" Burden Associated with Intravenous Treatment Regimens for Patients with Metastatic Pancreatic Ductal Adenocarcinoma

CO119 Real-World "Chair-Time" Burden Associated with Intravenous Treatment Regimens for Patients with Metastatic Pancreatic Ductal Adenocarcinoma

by MacEwan, J, Surinach, A, Lamarre, N, Cockrum, P
Published in Value in health (01.07.2022)

Get full text

Journal Article

1534P Multivariable analysis of real-world clinical outcomes associated with dose reductions (DRs) for patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan

1534P Multivariable analysis of real-world clinical outcomes associated with dose reductions (DRs) for patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan

by Abushahin, L., Cockrum, P., Surinach, A., Belanger, B.
Published in Annals of oncology (01.09.2020)

Get full text

Journal Article

1564P Clinical pathway implications and real-world characteristics and outcomes for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first line category 1 National Comprehensive Cancer Network (NCCN) regimens

1564P Clinical pathway implications and real-world characteristics and outcomes for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first line category 1 National Comprehensive Cancer Network (NCCN) regimens

by Kim, G., Cockrum, P., Arndorfer, S., Surinach, A.
Published in Annals of oncology (01.09.2020)

Get full text

Journal Article

PCN17 Real-World Impact of Prior Surgery on Outcomes of Patients with Metastatic Ductal Adenocarcinoma (mPDAC) Treated with Liposomal Irinotecan-Based Regimens

PCN17 Real-World Impact of Prior Surgery on Outcomes of Patients with Metastatic Ductal Adenocarcinoma (mPDAC) Treated with Liposomal Irinotecan-Based Regimens

by George, B., Cockrum, P., Lamarre, N., Surinach, A.
Published in Value in health (01.06.2021)

Get full text

Journal Article

PCN27 Real-World Characteristics and Outcomes of Patients with Metastatic Ductal Adenocarcinoma (MPDAC) Treated with Liposomal Irinotecan-Based Regimens By Race

PCN27 Real-World Characteristics and Outcomes of Patients with Metastatic Ductal Adenocarcinoma (MPDAC) Treated with Liposomal Irinotecan-Based Regimens By Race

by Kim, G.P., Cockrum, P., Lamarre, N., Surinach, A.
Published in Value in health (01.06.2021)

Get full text

Journal Article